<div id="readability-page-1"><h3>Claim 55% Off TipRanks</h3><ul><li>Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions </li><li> Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks </li></ul>CSPC Pharmaceutical Group ( (HK:1093) ) has issued an announcement. CSPC Pharmaceutical Group has disclosed unaudited first-quarter 2026 financial data for its Shenzhen-listed subsidiary, CSPC Innovation Pharmaceutical, prepared under China Accounting Standards. The company stressed that the figures relate only to the subsidiary, are unaudited and consolidated, and urged shareholders and potential investors to exercise caution when trading its securities. For the three months ended 31 March 2026, CSPC Innovation’s revenue rose 40.82% year on year to RMB 664.6 million, while its net loss attributable to shareholders deepened to RMB 93.9 million and operating cash flow turned more negative. Despite largely stable total assets and a modest decline in shareholder equity, profitability metrics deteriorated, suggesting higher investment or cost pressures even as top-line growth accelerates, which may weigh on near-term returns for stakeholders. The most recent analyst rating on (HK:1093) stock is a Buy with a HK$13.05 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page. More about CSPC Pharmaceutical Group CSPC Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company with operations spanning innovative drug research, development and manufacturing. Through subsidiaries such as CSPC Innovation Pharmaceutical Co., Ltd., it focuses on the Chinese market, including listings on the ChiNext Market of the Shenzhen Stock Exchange, and develops a portfolio of specialty and innovative medicines. YTD Price Performance: 6.52% Average Trading Volume: 105,300,194 Technical Sentiment Signal: Buy Current Market Cap: HK$103.3B Learn more about 1093 stock on TipRanks’ Stock Analysis page.</div>

01093

520690

159837

CSPC Pharmaceutical Group reported a 40.82% year-on-year revenue increase to RMB 664.6 million for Q1 2026, but its net loss deepened to RMB 93.9 million. The company cautioned that these figures are unaudited and pertain only to its subsidiary, CSPC Innovation Pharmaceutical. Despite stable total assets, profitability metrics worsened, indicating potential cost pressures. Analysts maintain a Buy rating on the stock (HK:1093) with a price target of HK$13.05.

Tip Ranks

CSPC PHARMA

Bosera Hang Seng SCHK Innovative Drug Select ETF

E Fund CSI Biotechnology Theme ETF

GF CSI HK Innovative Drugs Industry ETF(QDII)

China Universal CNI HK Connect Innovative Drugs Industry ETF

ChinaAMC CSI Biotechnology Theme ETF

Penghua CSI HK Connect Health Care Composite ETF

Guotai CSI Bio-medicine ETF

Hwabao WP Hang Seng SCHK Innovative Drug Select ETF

ChinaAMC Hang Seng Biotechnology Technology ETF(QDII)

Yinhua CSI Innovative Drugs Industry ETF

Bosera Hang Seng Health Care ETF(QDII)

Huatai-PB Hang Seng Innovative Drugs Industry ETF(QDII)

ChinaAMC SSE STAR Biology and Medicine ETF

E Fund Hang Seng SCHK Innovative Drug ETF

China Merchants CSI Biotechnology Theme ETF

E Fund CSI 300 Health Care ETF

Minsheng Royal CSI Biotechnology Theme ETF

Hwabao WP CSI Pharmaceuticals ETF

ChinaAMC SSE Health Care ETF Initiating Fund

Fullgoal Hang Seng SCHK Innovative Drug & Healthcare ETF

CSPC Innovation

CSPC Innovation Posts Strong Revenue Growth but Wider Losses in Q1 2026